Bueno v. Merck & Co., Inc.

District Court, S.D. California·Decided January 17, 2023·No. 3:22-cv-00522·Unknown

Opinion

Case No.: 22cv522-H(BLM) SPENCER BUENO; and RICHARD PARKER,

Plaintiffs, ORDER GRANTING JOINT MOTION FOR PROTECTIVE ORDER v.

MERCK & CO, INC.; MERCK SHARP & [ECF No. 31] DOHME CORP.; ORGANON & CO.; ORAGNON LLC; and DOES 1-10, inclusive,

Defendants. On January 6, 2023, the parties filed a Joint Motion for Determination of Dispute Regarding Proposed Stipulated Protective Order (“Motion”). ECF No. 31. The parties agree on all the terms of the Protective Order with the exception of the underlined language below: 7.1 Basic Principles. Received Party may use Protected Material that is disclosed or produced by another Party or by a Non-Party in connection with this Action only for prosecuting, defending, or attempting to settle the Action or another action involving substantially similar claims, against the same defendants (or some of the same defendants), on behalf of a plaintiff (or plaintiffs) represented by one or more of the same attorneys who represent any plaintiff in the Action. Such Protected Material may be disclosed only to the categories of persons and under the conditions described in this Order. When the Action has been terminated, a Receiving Party must comply with the provisions of Section 16 below. Motion at 2. Plaintiffs seek entry of the Protective Order with the disputed language, which they refer to as a “cross-use provision.” Id. at 3. Plaintiffs argue that the language should be included in the protective order because it “furthers the interests of efficiency and judicial economy and reduces cost.” Id. at 4. Plaintiffs state that without such language there would be repeated requests for the same documents, different judges ruling on the same discovery dispute,1 and a need to seek multiple amendments to the Protective Order. Id. at 4-6. Plaintiffs further indicate that their requested provision is not an effort to circumvent the Ninth Circuit’s holding in Foltz v. State Farm Mut. Auto. Ins. Co., 331 F.3d 1122 (9th Cir. 2003); instead, Plaintiffs argue that Foltz does not apply. Motion at 6. To support their position, Plaintiffs point to factual differences between the above-titled case and Foltz, and they claim courts across the country favor cross-use provisions in complex litigation. Id. at 6-8. Defendants argue that Foltz is applicable here and Plaintiffs’ requested language “impermissibly contravenes settled California procedure concerning disclosure of confidential material in a ‘collateral matter.’” Motion at 9. Defendants further indicate that many of the cases that Plaintiffs rely on pre-date Foltz or follow California procedure, which is inapplicable here. Motion at 13-15. Defendants also argue that following Foltz’s principles is especially appropriate here where there are “material differences seen throughout the Singulair cases[,]” as the various Plaintiffs “arrived at the medicine with their own unique medical history; was prescribed the medicine based on their own preexisting conditions . . . ; and allegedly experienced diverse effect and varied injuries at different periods during their course of usage.” Id. at 15. Defendants indicate that despite calling it a “cross-use provision,” Plaintiffs seek to share information with collateral litigants, making Foltz further applicable. Id. at 9. Defendants represent that a protective order without Plaintiffs’ requested language will not prevent the sharing of discovery. Id. at 17.

1 There are currently 357 cases, involving 363 plaintiffs, that “involve[] claims that branded or generic Singulair caused neuropsychiatric injuries in plaintiffs.” Motion at 4. These pending cases are being overseen by thirteen different judges and involve the same defendants. Id. Of the 357 cases, 356 “are led by the same attorneys representing Plaintiffs here, Kimberly Beck While the Ninth Circuit “strongly favors access to discovery materials to meet the needs of parties engaged in collateral litigation[,]” courts should not automatically approve a request to share discovery. Foltz v. State Farm Mut. Auto. Ins. Co., 331 F.3d 1122, 1131 (9th Cir. 2003) (citing Beckman Indus. Inc. v. Int’l Ins. Co., 966 F.2d 470, 475 (9th Cir. 1992)). Instead, under Foltz, the Ninth Circuit requires that a collateral litigant “demonstrate the relevance of the protected discovery materials to the collateral proceedings and its general discoverability therein.” Id. This requirement aims to “prevent[] collateral litigants from gaining access to discovery materials merely to subvert limitations on discovery in another proceeding.” Id. The Ninth Circuit explains: Allowing the parties to the collateral litigation to raise specific relevance and privilege objections to the production of any otherwise properly protected materials in the collateral courts further serves to prevent the subversion of limitations on discovery in the collateral proceedings. These procedures also preserve the proper role for each of the courts involved: the court responsible for the original protective order decides whether modifying the order will eliminate the potential for duplicative discovery. If the protective order is modified, the collateral courts may freely control the discovery processes in the controversies before them without running up against the protective order of another court. Id. The Court finds that Foltz governs here. Despite Plaintiffs referring to the disputed language as a “cross-use provision,” the results remain the same—sharing information with collateral litigants in collateral matters. Accordingly, the reasoning and holding in Foltz dictate the exclusion of Plaintiffs’ language. The Court agrees with Defendants and finds that Plaintiffs have failed to establish a legal or factual basis to permit the requested cross-use provision in the Protective Order. First, most of the cases Plaintiffs rely on to support their argument that cross-use provisions are favored across the country pre-date Foltz.2 Second, as noted by

Free access — add to your briefcase to read the full text and ask questions with AI

Bueno v. Merck & Co., Inc., (S.D. Cal. 2023).

Bueno v. Merck & Co., Inc. (Bueno v. Merck & Co., Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related